2022 World Conference on Lung Cancer (ePosters)-EP08.02-123. First Line Osimertinib in Lung Cancer Patients with Postoperative Recurrence

EP08.02-123. First Line Osimertinib in Lung Cancer Patients with Postoperative Recurrence

Pdf Summary

A study was conducted to evaluate the outcomes of lung cancer patients with EGFR mutations treated with osimertinib as first-line therapy after surgery. The study included patients who received osimertinib as a first-line treatment after surgery with curative intent. Patients who received adjuvant chemotherapy were also included. The duration of response, adverse events, and pattern of recurrence were analyzed. The results showed that 10 out of 16 patients were still on osimertinib, with 60% of them experiencing no dose reduction. Two patients developed severe adverse events leading to permanent discontinuation. Six out of 16 patients had CNS metastasis as the first site of postoperative recurrence. Three patients with deteriorated performance status caused by CNS metastasis died of lung cancer. One patient showed small cell transformation and was treated with a combination therapy. The study concluded that osimertinib as postoperative adjuvant therapy is highly significant considering the high incidence of CNS metastasis in lung cancer patients. However, patients with leptomeningeal metastasis (LM) as the site of first recurrence had a poor prognosis, suggesting the need for further investigations and potentially alternative treatment options for these patients. Overall, the study highlights the importance of osimertinib in the management of lung cancer patients with EGFR mutations after surgery.

Asset Subtitle

Atsushi Osoegawa

Meta Tag

Speaker Atsushi Osoegawa

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

lung cancer

EGFR mutations

osimertinib

first-line therapy

surgery

adjuvant chemotherapy

CNS metastasis

recurrence pattern

postoperative adjuvant therapy

management